Effects of Cilostazol on Dizocilpine-induced Hyperlocomotion and Prepulse Inhibition Deficits in Mice

참고문헌 (45)

1. Javitt DC, "Recent advances in the phencyclidine model of schizophrenia", Am J Psychiatry, 148, pp.1301~1308 (1991)
2. Olney JW, "Glutamate receptor dysfunction and schizophrenia", Arch Gen Psychiatry, 52, pp.998~1007 (1995)
3. Coyle JT, "The glutamatergic dysfunction hypothesis for schizophrenia", Harv Rev Psychiatry, 3, pp.241~253 (1996)
4. Krystal JH, "NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders", Harv Rev Psychiatry, 7, pp.125~143 (1999)
5. Hashimoto K, "Decreased serum levels of Dserine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia", Arch Gen Psychiatry, 60, pp.572~576 (2003)
6. Hashimoto K, "Glutamate hypothesis of schizophrenia and approach for possible thera-peutic drugs", Curr Med Chem CNS Agents, 4, pp.147~154 (2004)
7. Hashimoto K, "Dysfunction of glia-neuron communication in pathophysiology of schizophrenia", Curr Psychiatry Rev, 1, pp.151~163 (2005)
8. Kenji Hashimoto, "The NMDA Receptor Hypofunction Hypothesis for Schizophrenia and Glycine Modulatory Sites on the NMDA Receptors as Potential Therapeutic Drugs", Clinical Psychopharmacology and Neuroscience, 4(1), pp.3~10 (2006), 대한정신약물학회
9. Krystal JH, "Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses", Arch Gen Psychiatry, 51, pp.199~214 (1994)
10. Anand A, "Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists", Arch Gen Psychiatry, 57, pp.270~276 (2000)
11. Krystal JH, "Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia", Arch Gen Psychiatry, 59, pp.663~664 (2002)
12. Krystal JH, "Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function", Arch Gen Psychiatry, 62, pp.985~994 (2005)
13. benzodiazepine maleate, "Neuropsychopharmacology", 2002, 456~467
14. Okamura N, "Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine- induced neuropathological changes in rat retrosplenial cortex", Brain Res, 992, pp.114~119 (2003)
15. Okamura N, "Adenosine A1 receptor agonists block the neuropathological changes in rat retrosplenial cortex after administration of the NMDA receptor antagonist dizocilpine", Neuropsychopharmacology, 29, pp.544~550 (2004)
16. Braff DL, "Sensorimotor gating and schizophrenia. Human and animal model studies", Arch Gen Psychiatry, 47, pp.181~188 (1990)
17. Swerdlow NR, "Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients", Arch Gen Psychiatry, 51, pp.139~154 (1994)
18. Swerdlow NR, "Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia", Schizophr Bull, 24, pp.285~301 (1998)
19. Geyer MA, "Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review", Psychopharmacology (Berl), 156, pp.117~154 (2001)
20. Perry W, "Sensorimotor gating and thought disturbance measured in close temporal proximity in schizophrenic patients", Arch Gen Psychiatry, 56, pp.277~281 (1999)
21. Varty GB, "M100907, a serotonin 5- HT2A receptor antagonist and putative antipsychotic, blocks dizocilpine-induced prepulse inhibition deficits in Sprague- Dawley and Wistar rats", Neuropsychopharmacology, 20, pp.311~321 (1999)
22. Yee BK, "The effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice", Neuropsychopharmacology, 29, pp.1865~1877 (2004)
23. Long LE, "Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice", Neuropsychopharmacology, 31, pp.795~803 (2006)
24. Zhang L, "Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine", Neuropsychopharmacology, 32, pp.2004~2010 (2007)
25. Hashimoto K, "Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of d-serine in attenuating prepulse inhibition deficits after administration of dizocilpine", Biol Psychiatry, 65, pp.1103~1106 (2009)
26. Horio M, "Effects of D-amino acid oxidase inhibitor on the extracellular D-alanine levels and the efficacy of D-alanine on dizocilpine-induced prepulse inhibition deficits in mice", Open Clin Chem J, 2, pp.16~21 (2009)
27. Kimura Y, "Selective type III phosphodiesterase inhibitor as an antithrombotic agent", Nippon Yakurigaku Zasshi, 106, pp.205~216 (1995)
28. Schröor K, "The pharmacology of cilostazol", Diabetes Obes Metab, 4(2), pp.14~19 (2002)
29. Kumar M, "Cilostazol: a new drug in the treatment intermittent claudication", Recent Pat Cardiovasc Drug Discov, 2, pp.181~185 (2007)
30. Hong KW, "Cilostazol: therapeutic potential against focal cerebral ischemic damage", Curr Pharm Des, 12, pp.565~573 (2006)
31. Honda F, "Cilostazol attenuates gray and white matter damage in a rodent model of focal cerebral ischemia", Stroke, 37, pp.223~228 (2006)
32. Watanabe T, "Cilostazol protects against brain white matter damage and cognitive impairment in a rat model of chronic cerebral hypoperfusion", Stroke, 37, pp.1539~1545 (2006)
33. Lee JH, "Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion", Brain Res, 1082, pp.182~191 (2006)
34. Wakida K, "Cilostazol reduces ischemic brain damage partly by inducing metallothionein-1 and -2", Brain Res, 1116, pp.187~193 (2006)
35. Lee JH, "Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat", Brain Res, 1152, pp.182~190 (2007)
36. Lee JH, "Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats", Brain Res, 1185, pp.246~255 (2007)
37. Lee JH, "Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury", CNS Neurosci Ther, 14, pp.143~152 (2008)
38. Siuciak JA, "The role of phosphodiesterases in schizophrenia: therapeutic implications", CNS Drugs, 22, pp.983~993 (2008)
39. Choi JM, "Neuroprotective effect of cilostazol against focal cerebral ischemia via antiapoptotic action in rats", J Pharmacol Exp Ther, 300, pp.787~793 (2002)
40. Lee JH, "Cilostazol reduces brain lesion induced by focal cerebral ischemia in rats--an MRI study", Brain Res, 994, pp.91~98 (2003)
41. Halene TB, "PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia", Drug Discovery Today, 12, pp.870~878 (2007)
42. Hashimoto K, "Effects of cilostazol on cognitive deficits in mice after repeated administration of phencyclidine", Psychopharmacol Neurosci, 8, pp.26~29 (2010)
43. Nishimura K, "Cilostazol, a cAMP phosphodiesterase 3 inhibitor, in the treatment of poststroke depression", J Neuropsychiatry Clin Neurosci, 19, pp.471~472 (2007)
44. Baba H, "Seven cases of latelife depression treated with cilostazol-augmented therapy", J Clin Psychopharmacol, 27, pp.727~728 (2007)
45. Takahashi K, "Novel augmentation therapy with cilostazol for the geriatric major depressive disorder patient with deep white matter hyperintensities on T2-weighted brain MRI: a case report", Pharmacopsychiatry, 41, pp.37~39 (2008)

관련 논문AI추천